Literature DB >> 20803284

Evaluation of CEM43 degrees CT90 thermal dose in superficial hyperthermia: a retrospective analysis.

Maarten de Bruijne1, Bronno van der Holt, Gerard C van Rhoon, Jacoba van der Zee.   

Abstract

BACKGROUND AND
PURPOSE: Prospective use of the CEM43 degrees CT90 thermal dose parameter has been proposed for hyperthermia treatments. This study evaluates the CEM43 degrees CT90 parameter by means of a retrospective analysis of recurrent breast cancer patients receiving reirradiation plus hyperthermia.
MATERIAL AND METHODS: CEM43 degrees CT90 was calculated for 72 patients who received 8 x 4 Gy reirradiation plus 8 x 1 h hyperthermia for adenocarcinoma recurrences at the chest wall. Associations of prognostic factors CEM43 degrees CT90 and tumor maximum diameter with endpoints complete response (CR), duration of local control (DLC), and overall survival (OS) were determined.
RESULTS: A highly significant inverse association between CEM43 degrees CT90 and tumor maximum diameter (rho = -0.7, p < 1e-6) was found. The association between CR and CEM43 degrees CT90 was not significant (p > or = 0.7). CEM43 degrees CT90 was associated with DLC. Both CEM43 degrees CT90 and tumor maximum diameter had a significant association with survival (p < or = 0.01). The association with thermal dose, when adjusted for tumor maximum diameter, was not significant for either CR, DLC, or OS (p > 0.2).
CONCLUSION: In this retrospective study, no clear CEM43 degrees CT90 thermal dose targets or associations with clinical endpoints could be established.

Entities:  

Mesh:

Year:  2010        PMID: 20803284     DOI: 10.1007/s00066-010-2146-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  24 in total

1.  Kadota Fund International Forum 2004. Application of thermal stress for the improvement of health, 15-18 June 2004, Awaji Yumebutai International Conference Center, Awaji Island, Hyogo, Japan. Final report.

Authors:  Tsutomu Sugahara; J van der Zee; Harm H Kampinga; Zeliko Vujaskovic; Motoharu Kondo; Takeo Ohnishi; Gloria Li; Heon J Park; Dennis B Leeper; Valentina Ostapenko; Elizabeth A Repasky; Masami Watanabe; Chang W Song
Journal:  Int J Hyperthermia       Date:  2008-03       Impact factor: 3.914

2.  A 433 MHz Lucite cone waveguide applicator for superficial hyperthermia.

Authors:  G C van Rhoon; P J Rietveld; J van der Zee
Journal:  Int J Hyperthermia       Date:  1998 Jan-Feb       Impact factor: 3.914

3.  Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial.

Authors:  M Sherar; F F Liu; M Pintilie; W Levin; J Hunt; R Hill; J Hand; C Vernon; G van Rhoon; J van der Zee; D G Gonzalez; J van Dijk; J Whaley; D Machin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-09-01       Impact factor: 7.038

Review 4.  Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment.

Authors:  C W Song; H J Park; C K Lee; R Griffin
Journal:  Int J Hyperthermia       Date:  2005-12       Impact factor: 3.914

5.  Superficial hyperthermia and irradiation for recurrent breast carcinoma of the chest wall: prognostic factors in 196 tumors.

Authors:  H K Lee; A G Antell; C A Perez; W L Straube; G Ramachandran; R J Myerson; B Emami; E P Molmenti; A Buckner; M A Lockett
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-15       Impact factor: 7.038

Review 6.  Arrhenius relationships from the molecule and cell to the clinic.

Authors:  W C Dewey
Journal:  Int J Hyperthermia       Date:  1994 Jul-Aug       Impact factor: 3.914

7.  Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer.

Authors:  Valeria Milani; Montserrat Pazos; Rolf Dieter Issels; Veit Buecklein; Sultan Rahman; Katharina Tschoep; Pamela Schaffer; Ralf Wilkowski; Eckhart Duehmke; Moshe Schaffer
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

8.  Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment.

Authors:  J R Oleson; T V Samulski; K A Leopold; S T Clegg; M W Dewhirst; R K Dodge; S L George
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-01-15       Impact factor: 7.038

9.  Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a Report by the Radiation Therapy Oncology Group.

Authors:  C A Perez; B Gillespie; T Pajak; N B Hornback; B Emami; P Rubin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

10.  Immediate reconstruction with an expander/implant following ablatio mammae because of breast cancer : side effects and cosmetic results after adjuvant chest wall radiotherapy.

Authors:  Marc D Piroth; Daniela M Piroth; Michael Pinkawa; Seth G Woodruff; Richard Holy; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

View more
  12 in total

1.  Quality assurance for clinical studies in regional deep hyperthermia.

Authors:  Gregor Bruggmoser; Stefan Bauchowitz; Richard Canters; Hans Crezee; Michael Ehmann; Johanna Gellermann; Ulf Lamprecht; Nicoletta Lomax; Marc Benjamin Messmer; Oliver Ott; Sultan Abdel-Rahman; Rolf Sauer; Manfred Schmidt; Andreas Thomsen; Rüdiger Wessalowski; Gerard van Rhoon
Journal:  Strahlenther Onkol       Date:  2011-09-19       Impact factor: 3.621

Review 2.  Ultrasound Hyperthermia Technology for Radiosensitization.

Authors:  Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen
Journal:  Ultrasound Med Biol       Date:  2019-02-14       Impact factor: 2.998

3.  Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia.

Authors:  G Bruggmoser; S Bauchowitz; R Canters; H Crezee; M Ehmann; J Gellermann; U Lamprecht; N Lomax; M B Messmer; O Ott; S Abdel-Rahman; M Schmidt; R Sauer; A Thomsen; R Wessalowski; G van Rhoon
Journal:  Strahlenther Onkol       Date:  2012-09       Impact factor: 3.621

Review 4.  Gesture as representational action: A paper about function.

Authors:  Miriam A Novack; Susan Goldin-Meadow
Journal:  Psychon Bull Rev       Date:  2017-06

5.  Improved Hyperthermia Treatment of Tumors Under Consideration of Magnetic Nanoparticle Distribution Using Micro-CT Imaging.

Authors:  H Dähring; J Grandke; U Teichgräber; I Hilger
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 6.  Photothermal therapies to improve immune checkpoint blockade for cancer.

Authors:  Preethi B Balakrishnan; Elizabeth E Sweeney; Anvitha S Ramanujam; Rohan Fernandes
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

7.  Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall.

Authors:  M Linthorst; A N van Geel; E A Baartman; S B Oei; W Ghidey; G C van Rhoon; J van der Zee
Journal:  Strahlenther Onkol       Date:  2013-04-04       Impact factor: 3.621

8.  Benefit of replacing the Sigma-60 by the Sigma-Eye applicator. A Monte Carlo-based uncertainty analysis.

Authors:  R A M Canters; M M Paulides; M Franckena; J W Mens; G C van Rhoon
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

9.  Procedure for creating a three-dimensional (3D) model for superficial hyperthermia treatment planning.

Authors:  Marianne Linthorst; Tomas Drizdal; Hans Joosten; Gerard C van Rhoon; Jacoba van der Zee
Journal:  Strahlenther Onkol       Date:  2011-11-25       Impact factor: 3.621

10.  High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area.

Authors:  Susanne Kossatz; Robert Ludwig; Heidi Dähring; Volker Ettelt; Gabriella Rimkus; Marzia Marciello; Gorka Salas; Vijay Patel; Francisco J Teran; Ingrid Hilger
Journal:  Pharm Res       Date:  2014-06-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.